Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association

Bone

Volumn 75, Issue , 2015, Pages 96-104

  Martin, Anthony ^a   Xiong, Jian ^a   Koromila, Theodora ^a   Ji, Jie S ^a   Chang, Stephanie ^a   Song, Yae S ^a   Miller, Jonathan L ^a   Han, Chun Ya ^b   Kostenuik, Paul ^b   Krum, Susan A ^c,e   Chimge, Nyam Osor ^a   Gabet, Yankel ^d   Frenkel, Baruch ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Postmenopausal osteoporosis; Protein trafficking; Secretion; TRAP

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE; TAMOXIFEN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; ESTROGEN; RUNX2 PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELLULAR DISTRIBUTION; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION; IMMUNOFLUORESCENCE MICROSCOPY; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MEMBRANE ASSOCIATION; MEMBRANE BIOLOGY; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOUSE; NEWBORN; NONHUMAN; OC GENE; OPG GENE; OSTEOBLAST; OSTEOBLAST DRIVEN OSTEOCLASTOGENESIS; OSTEOCLAST; OSTEOCLASTOGENESIS; OSX GENE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PSTPIP2 GENE; RANKL GENE; REGULATORY MECHANISM; SPLEEN CELL; WILD TYPE; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DNA MICROARRAY; FEMALE; METABOLISM; OSTEOLYSIS; PHYSIOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; FEMALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; OSTEOCLASTS; POLYMERASE CHAIN REACTION; RANK LIGAND;

EID: 84923932220     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.02.007     Document Type: Article

References (62)

1. Ducy P., Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 1995, 15:1858-1869.
2. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
3. Banerjee C., McCabe L.R., Choi J.Y., Hiebert S.W., Stein J.L., Stein G.S. Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem 1997, 66:1-8.
4. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
5. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
6. Geoffroy V., Kneissel M., Fournier B., Boyde A., Matthias P. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 2002, 22:6222-6233.
7. Maruyama Z., Yoshida C.A., Furuichi T., Amizuka N., Ito M., Fukuyama R., et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn 2007, 236:1876-1890.
8. Baniwal S.K., Shah P.K., Shi Y., Haduong J.H., Declerck Y.A., Gabet Y., et al. Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporos Int 2011, 23:1399-1413.
9. Liu W., Toyosawa S., Furuichi T., Kanatani N., Yoshida C., Liu Y., et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001, 155:157-166.
10. Adhami M.D., Rashid H., Chen H., Clarke J.C., Yang Y., Javed A. Loss of Runx2 in committed osteoblasts impairs postnatal skeletogenesis. J Bone Miner Res 2014, 30:71-82.
11. Suda T., Takahashi N., Martin T.J. Modulation of osteoclast differentiation. Endocr Rev 1992, 13:66-80.
12. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
13. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
14. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
15. Byon C.H., Sun Y., Chen J., Yuan K., Mao X., Heath J.M., et al. Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol 2011, 31:1387-1396.
16. O'Brien C.A., Kern B., Gubrij I., Karsenty G., Manolagas S.C. Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. Bone 2002, 30:453-462.
17. O'Brien C.A. Control of RANKL gene expression. Bone 2010, 46:911-919.
18. Services USDoHaH Bone health and osteoporosis: a report of the Surgeon General 2004, U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD. 2010/10/15 ed.
19. Manolagas S.C., O'Brien C.A., Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol 2013, 9:699-712.
20. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010, 95:3569-3577.
21. Khalid O., Baniwal S.K., Purcell D.J., Leclerc N., Gabet Y., Stallcup M.R., et al. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology 2008, 149:5984-5995.
22. Gabet Y., Noh T., Lee C., Frenkel B. Developmentally regulated inhibition of cell cycle progression by glucocorticoids through repression of cyclin A transcription in primary osteoblast cultures. J Cell Physiol 2011, 226:991-998.
23. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A 1990, 87:7260-7264.
24. Baniwal S.K., Khalid O., Gabet Y., Shah R.R., Purcell D.J., Mav D., et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010, 9:258.
25. Kariya Y., Honma M., Aoki S., Chiba A., Suzuki H. Vps33a mediates RANKL storage in secretory lysosomes in osteoblastic cells. J Bone Miner Res 2009, 24:1741-1752.
26. Singh P.P., van der Kraan A.G., Xu J., Gillespie M.T., Quinn J.M. Membrane-bound receptor activator of NFkappaB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors. Biochem Biophys Res Commun 2012, 422:48-53.
27. Cope A.P. Arthritis research: methods and protocols 2007, Springer Science & Business Media.
28. Enomoto H., Shiojiri S., Hoshi K., Furuichi T., Fukuyama R., Yoshida C.A., et al. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. J Biol Chem 2003, 278:23971-23977.
29. Almeida M., Martin-Millan M., Ambrogini E., Bradsher R., Han L., Chen X.D., et al. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res 2010, 25:769-781.
30. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007, 130:811-823.
31. Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P., Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000, 127:4277-4291.
32. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
33. Saika M., Inoue D., Kido S., Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001, 142:2205-2212.
34. Little G.H., Noushmehr H., Baniwal S.K., Berman B.P., Coetzee G.A., Frenkel B. Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res 2012, 40:3538-3547.
35. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
36. Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1996, 137:2187-2190.
37. Kita A., Higa M., Doi A., Satoh R., Sugiura R. Imp2, the PSTPIP homolog in fission yeast, affects sensitivity to the immunosuppressant FK506 and membrane trafficking in fission yeast. Biochem Biophys Res Commun 2015, 457:273-279.
38. Das S., Crockett J.C. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013, 7:435-448.
39. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008, 27:535-545.
40. Chimge N.O., Frenkel B. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 2013, 32:2121-2130.
41. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2011, 468:98-102.
42. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275:768-775.
43. Manolagas S.C., O'Brien C.A., Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol 2013, 9:699-712.
44. Windahl S.H., Borjesson A.E., Farman H.H., Engdahl C., Moverare-Skrtic S., Sjogren K., et al. Estrogen receptor-alpha in osteocytes is important for trabecular bone formation in male mice. Proc Natl Acad Sci U S A 2013, 110:2294-2299.
45. Kartsogiannis V., Zhou H., Horwood N.J., Thomas R.J., Hards D.K., Quinn J.M., et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999, 25:525-534.
46. Mueller R.J., Richards R.G. Immunohistological identification of receptor activator of NF-kappaB ligand (RANKL) in human, ovine and bovine bone tissues. J Mater Sci Mater Med 2004, 15:367-372.
47. Silvestrini G., Ballanti P., Patacchioli F., Leopizzi M., Gualtieri N., Monnazzi P., et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol 2005, 36:59-67.
48. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
49. Kalajzic I., Matthews B.G., Torreggiani E., Harris M.A., Divieti Pajevic P., Harris S.E. In vitro and in vivo approaches to study osteocyte biology. Bone 2013, 54:296-306.
50. Inada M., Yasui T., Nomura S., Miyake S., Deguchi K., Himeno M., et al. Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn 1999, 214:279-290.
51. Bronckers A.L., Sasaguri K., Engelse M.A. Transcription and immunolocalization of Runx2/Cbfa1/Pebp2alphaA in developing rodent and human craniofacial tissues: further evidence suggesting osteoclasts phagocytose osteocytes. Microsc Res Tech 2003, 61:540-548.
52. Amir L.R., Jovanovic A., Perdijk F.B., Toyosawa S., Everts V., Bronckers A.L. Immunolocalization of sibling and RUNX2 proteins during vertical distraction osteogenesis in the human mandible. J Histochem Cytochem 2007, 55:1095-1104.
53. Honma M., Ikebuchi Y., Kariya Y., Hayashi M., Hayashi N., Aoki S., et al. RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J Bone Miner Res 2013, 28:1936-1949.
54. Yu J., Adisetiyo H., Little G.H., Vangsness C.T., Jiang J., Sternberg H., et al. Initial characterization of osteoblast differentiation and loss of RUNX2 stability in the newly established SK11 human embryonic stem cell-derived cell line. J Cell Physiol 2014, 230:237-241.
55. Komori T. Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 2010, 658:43-49.
56. Huang S., Shao G., Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem 1998, 273:15933-15939.
57. Galli G.G., Honnens de Lichtenberg K., Carrara M., Hans W., Wuelling M., Mentz B., et al. Prdm5 regulates collagen gene transcription by association with RNA polymerase II in developing bone. PLoS Genet 2012, 8:e1002711.
58. Suda M., Ogawa Y., Tanaka K., Tamura N., Yasoda A., Takigawa T., et al. Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc Natl Acad Sci U S A 1998, 95:2337-2342.
59. Kajita M., Ezura Y., Iwasaki H., Ishida R., Yoshida H., Kodaira M., et al. Association of the -381T/C promoter variation of the brain natriuretic peptide gene with low bone-mineral density and rapid postmenopausal bone loss. J Hum Genet 2003, 48:77-81.
60. Mankin H.J., Dorfman H., Lippiello L., Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971, 53:523-537.
61. Cvetkovic M., Mann G.N., Romero D.F., Liang X.G., Ma Y., Jee W.S., et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994, 57:1231-1237.
62. He N., Xiao Z., Yin T., Stubbs J., Li L., Quarles L.D. Inducible expression of Runx2 results in multiorgan abnormalities in mice. J Cell Biochem 2011, 112:653-665.